scholarly journals Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

2019 ◽  
Vol 49 (10) ◽  
pp. 1314-1322 ◽  
Author(s):  
Amanda J. Nicoll ◽  
Stuart K. Roberts ◽  
Ricky Lim ◽  
Joanne Mitchell ◽  
Martin Weltman ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Immunoglobulin G ◽  
Standard Therapy ◽  
Older Age ◽  
Beneficial Response

scholarly journals Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis in Patients Refractory to Standard Therapy

2004 ◽  
Vol 18 (5) ◽  
pp. 321-326 ◽  
Author(s):  
Shane M Devlin ◽  
Mark G Swain ◽  
Stefan J Urbanski ◽  
Kelly W Burak
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Alanine Aminotransferase ◽  
Standard Therapy ◽  
Conventional Treatment ◽  
Case Series ◽  
Therapeutic Options ◽  
Sparing Effect ◽  
Histological Remission ◽  
Steroid Sparing

There are limited therapeutic options available for patients with autoimmune hepatitis in whom conventional treatment fails. A case series of five patients unresponsive to or unable to take azathioprine, 6-mercaptopurine or corticosteroids who were treated with mycophenolate mofetil (MMF) is reported. While on MMF, alanine aminotransferase normalized or remained normal in all patients. MMF had a steroid-sparing effect and histological remission was demonstrated in one patient after seven months of MMF. One patient experienced an uncomplicated episode of pyelonephritis. In conclusion, MMF can effectively induce and maintain remission in refractory autoimmune hepatitis patients.

Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine

2019 ◽  
Vol 51 (2) ◽  
pp. 253-257 ◽  
Author(s):  
Georgios Giannakopoulos ◽  
Hans Verbaan ◽  
Inga-Lill Friis-Liby ◽  
Per Sangfelt ◽  
Nils Nyhlin ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Standard Therapy

Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

2018 ◽  
Vol 16 (2) ◽  
pp. 268-277 ◽  
Author(s):  
Stuart K. Roberts ◽  
Ricky Lim ◽  
Simone Strasser ◽  
Amanda Nicoll ◽  
Alessia Gazzola ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Standard Therapy ◽  
Efficacy And Safety

scholarly journals Treating Critically Ill Patients Experiencing SARS-CoV-2 Severe Infection with Ig-M and Ig-A Enriched Ig-G Infusion

Antibiotics ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 930
Author(s):  
Alberto Corona ◽  
Giuseppe Richini ◽  
Sara Simoncini ◽  
Marta Zangrandi ◽  
Monica Biasini ◽  
...  
Keyword(s):  
Immunoglobulin G ◽  
Standard Therapy ◽  
Severe Infection ◽  
Treated Group ◽  
Simplified Acute Physiology Score ◽  
Retrospective Case ◽  
Baseline Characteristics ◽  
Time Of Admission ◽  
Ig G ◽  
Control Study

SARS-CoV-2 in patients who need intensive care unit (ICU) is associated with a mortality rate ranging from 10 to 40–45%, with an increase in morbidity and mortality in presence of sepsis. We hypothesized that IgM and IgA enriched immunoglobulin G may support the sepsis-related phase improving patient outcome. We conducted a retrospective case–control study on 47 consecutive patients admitted to our ICU. At the time of admission, patients received anticoagulants (heparin sodium) together with the standard supportive treatment. We decided to add IgM and IgA enriched immunoglobulin G to the standard therapy. Patients receiving IgM and IgA enriched immunoglobulin G were compared with patients with similar baseline characteristics and treatment, receiving only standard therapy. The mortality resulted significantly higher in patients treated with standard therapy only (56.5 vs. 37.5%, p < 0.01) and, at day 7, the probability of dying was 3 times higher in this group. Variable life adjustment display (VLAD) was 2.4 and -2.2 (in terms of lives saved in relation with those expected and derived from Simplified Acute Physiology Score II) in the treated and not treated group, respectively. The treatment based on IgM and IgA enriched immunoglobulin G infusion seems to give an advantage on survival in SARS-CoV-2 severe infection.

Low dose tacrolimus for the treatment of autoimmune hepatitis resistant to standard therapy

2003 ◽  
Vol 124 (4) ◽  
pp. A785 ◽  
Author(s):  
Sajid Jalil ◽  
Ahmet Gurakar ◽  
Harlan Wright ◽  
Ted Bader ◽  
Anthony Sebastian ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Standard Therapy ◽  
Low Dose

Goose Bumps and Memory Loss

2021 ◽  
pp. 96-97
Author(s):  
Jeffrey W. Britton ◽  
Bhavya Narapureddy ◽  
Divyanshu Dubey
Keyword(s):  
Mycophenolate Mofetil ◽  
Cognitive Dysfunction ◽  
Immunoglobulin G ◽  
Oral Prednisone ◽  
Memory Loss ◽  
Oligoclonal Bands ◽  
Fluid Analysis ◽  
Autoimmune Epilepsy ◽  
Fluid Attenuated Inversion Recovery ◽  
Interictal Discharges

A 46-year-old man had an episode of loss of awareness while driving home. He was found in a cul de sac by his neighbor and was acting confused. He was brought to the emergency department; while there, he started having recurrent episodes of goose bumps (goose flesh) involving half of his body associated with a “wavelike” sensation that would typically begin in the lower extremities and spread upward. He also had some speech difficulty. Physical and neurologic examinations were unremarkable, except for mild cognitive deficits. Video electroencephalographic monitoring showed frequent independent left and right temporal ictal and interictal discharges. Magnetic resonance imaging of the brain showed fluid-attenuated inversion recovery hyperintensity in the bilateral hippocampi. Cerebrospinal fluid analysis showed a mildly increased total protein concentration but no supernumerary oligoclonal bands and normal nucleated cell count and immunoglobulin G index. Serum autoimmune epilepsy evaluation was remarkable for leucine-rich, glioma-inactivated protein 1-immunoglobulin G seropositivity. The patient was diagnosed with leucine-rich, glioma-inactivated protein 1- immunoglobulin G antibody–associated autoimmune seizures presenting with pilomotor seizures. Before autoimmune work-up, the patient had been treated with a gradual escalation of antiseizure medications. The seizures continued. He was subsequently started on intravenous methylprednisolone. He was seizure free and was transitioned to an oral prednisone taper. He was subsequently started on a 6-week regimen of intravenous immunoglobulin. He was also started on mycophenolate mofetil. On follow-up clinic visits, the patient had no recurrence of seizures and disclosed no cognitive dysfunction except for mild inattention. Three years after the patient’s initial episode, the antiseizure medications and mycophenolate mofetil were gradually tapered, without recurrence. Leucine-rich, glioma-inactivated protein 1-immunoglobulin G–associated autoimmunity is typically seen among older patients (>50 years), more commonly men. Symptoms commonly include seizures and cognitive dysfunction, presenting as memory loss and disorientation.

scholarly journals Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

2017 ◽  
Vol 15 (12) ◽  
pp. 1950-1956.e1 ◽  
Author(s):  
Cumali Efe ◽  
Hannes Hagström ◽  
Henriette Ytting ◽  
Rahima A. Bhanji ◽  
Niklas F. Müller ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Second Line ◽  
Efficacy And Safety ◽  
Second Line Therapy ◽  
Line Therapy

Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis

2019 ◽  
Vol 31 (7) ◽  
pp. 873-877 ◽  
Author(s):  
Zhen-Jun Yu ◽  
Lu-Lu Zhang ◽  
Ting-Ting Huang ◽  
Jian-Sheng Zhu ◽  
Ze-Bao He
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Standard Treatment
Sign in / Sign up

Export Citation Format

Share Document